WSJ.com: US Business
Genetic Test Service Hits FDA Roadblock
[unable to retrieve full-text content]The FDA ordered genetic-testing startup 23andMe to stop marketing its mail-order DNA kit, citing the risk that false results could cause consumers to undergo unnecessary health procedures such as breast-cancer surgery.
0 comments:
Post a Comment